

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**






PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : <b>C07D 473/16, A61K 31/505</b></p>	<p><b>A1</b></p>	<p>(11) International Publication Number: <b>WO 98/16528</b> (43) International Publication Date: 23 April 1998 (23.04.98)</p>
<p>(21) International Application Number: PCT/US97/19472 (22) International Filing Date: 10 October 1997 (10.10.97) (30) Priority Data: 60/028,306 11 October 1996 (11.10.96) US (71) Applicants: CHIRON CORPORATION [US/US]; 4560 Horton Street, Emeryville, CA 94608 (US). THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA 94612-3550 (US). (72) Inventors: SCHULTZ, Peter; 4616 Rising Hill Court, Oakland, CA 94619 (US). RING, David, B.; 2375 Cowper Street, Palo Alto, CA 94301 (US). HARRISON, Stephen, D.; 1369 Francisco Street, Berkeley, CA 94702 (US). BRAY, Andrew, M.; 48 Western Road, Boronia, VIC 3155 (AU). (74) Agents: FUJITA, Sharon, M. et al.; Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA 94662-8097 (US).</p>		<p>(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>

(54) Title: PURINE INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 (GSK3)



(1)

(57) Abstract

Compounds of formula (1) wherein R<sub>1</sub> is alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl, substituted with 0-3 substituents selected from lower alkyl, halo, hydroxy, lower alkoxy, amino, lower alkyl-amino, and nitro; R<sub>2</sub> is hydroxy, amino, or lower alkoxy; R<sub>3</sub> is H, lower alkyl, lower acyl, lower alkoxy-acyl, or amino-acyl; R<sub>4</sub> is H or lower alkyl; and pharmaceutically acceptable salts and esters thereof; are effective inhibitors of GSK3.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## PURINE INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 (GSK3)

### Government License Rights

The U.S. Government has rights in this invention as provided for by the terms of contract No. DE-AC03-76SF00098 awarded by the Department of Energy (DOE) and by  
5 the terms of Postdoctoral Fellowships awarded by the National Science Foundation and the American Cancer Society.

### Description

#### Field of the Invention

This invention relates generally to the field of medicinal chemistry, and specifically  
10 ally to compounds which inhibit the activity of glycogen synthase kinase 3 (GSK3).

#### Background of the Invention

Glycogen synthase kinase 3 (GSK3) is a proline-directed serine/threonine kinase originally identified as an activity that phosphorylates glycogen synthase, as described in Woodgett, Trends Biochem Sci (1991) 16:177-81. GSK3 consists of two isoforms,  $\alpha$   
15 and  $\beta$ , and is constitutively active in resting cells, inhibiting glycogen synthase by direct phosphorylation. Upon insulin activation, GSK3 is inactivated, thereby allowing the activation of glycogen synthase and possibly other insulin-dependent events. Subsequently, it has been shown that GSK3 activity is inactivated by other growth factors or hormones, that, like insulin, signal through receptor tyrosine kinases (RTKs).  
20 Examples of such signaling molecules include IGF-1 and EGF as described in Saito *et al*, Biochem J (1994) 303:27-31; Welsh *et al*, Biochem J (1993) 294:625-29; and Cross *et al*, Biochem J (1994) 303:21-26. GSK3 has been shown to phosphorylate  $\beta$ -catenin as described in Peifer *et al*, Develop Biol (1994) 166:543-56.


Other activities of GSK3 in a biological context include GSK3's ability to  
25 phosphorylate tau protein *in vitro* as described in Mandelkow and Mandelkow, Trends in Biochem Sci (1993) 18:480-83; Mulot *et al*, FEBS Lett (1994) 349:359-64; and Lovestone *et al*, Curr Biol (1995) 4:1077-86; and in tissue culture cells as described in

Latimer *et al*, FEBS Lett (1995) 365:42-46. Phosphorylation of tau and polymerization of the phosphorylated tau is believed to allow formation of paired helical filaments that are characteristic of Alzheimer's disease. Thus, inhibition of GSK3 may be useful to treat or inhibit these disorders.

- 5 It would be advantageous to develop a method for screening for inhibitors of GSK3 for use and administration in all contexts where inhibition of GSK3 activity could have a favorable effect.

### Summary of the Invention

- 10 We have now invented compounds of formula 1 which inhibit the activity of GSK3:



- 15 where R<sub>1</sub> is alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl, substituted with 0-3 substituents selected from lower alkyl, halo, hydroxy, lower alkoxy, amino, lower alkyl-amino, and nitro; R<sub>2</sub> is hydroxy, amino, or lower alkoxy; R<sub>3</sub> is H, lower alkyl, lower acyl, lower alkoxy-acyl, or amino-acyl; R<sub>4</sub> is H or lower alkyl; and pharmaceutically acceptable salts and esters thereof.

Another aspect of the invention is a pharmaceutical composition, comprising a compound of formula 1 and a pharmaceutically acceptable excipient.


Another aspect of the invention is a method for inhibiting GSK3, by contacting it with a compound of formula 1.

- 20 Another aspect of the invention is a method for treating an indication modulated by GSK3, comprising administering a compound of formula 1 to a subject in need thereof.

### Detailed Description

#### Definitions

The term "compound of formula 1" refers to compounds having the general structure:



wherein

$R_1$  is alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl, substituted with 0-3 substituents selected from lower alkyl, halo, hydroxy, lower alkoxy, amino, lower alkyl-amino, and nitro;

$R_2$  is hydroxy, amino, or lower alkoxy;

$R_3$  is H, lower alkyl, lower acyl, lower alkoxy-acyl, or amino-acyl;

$R_4$  is H or lower alkyl;

and pharmaceutically acceptable salts and esters thereof.

The term "alkyl" as used herein refers to saturated hydrocarbon radicals containing from 1 to 12 carbon atoms, inclusive. Alkyl radicals may be straight, branched, or cyclic. Exemplary alkyl radicals include n-pentyl, n-hexyl, n-octyl, n-dodecyl, 2-dodecyl, 3,5-diethylcyclohexyl, duryl, and the like. The term "lower alkyl" as used herein refers to straight, branched, and cyclic chain hydrocarbon radicals having from 1 to 8 carbon atoms, such as methyl, ethyl, propyl, isopropyl, n-butyl, s-butyl, t-butyl, n-pentyl, n-hexyl, cyclopentyl, cyclohexyl, 2-methylcyclopentyl, and the like. "Alkoxy" refers to radicals of the formula -OR, where R is alkyl as defined above:

"lower alkoxy" refers to alkoxy radicals wherein R is lower alkyl. "Hydroxy-lower alkyl" refers to radicals of the formula HO-R-, where R is lower alkylene of 1 to 8 carbons, and may be straight, branched, or cyclic. "Hydroxy-lower alkoxy" refers to radicals of the formula HO-R-O-, where R is lower alkylene of 1 to 8 carbons, and may be straight, branched, or cyclic. "Lower alkoxy-lower alkyl" refers to groups of the formula  $R_aO-R_b-$ , where  $R_a$  and  $R_b$  are each independently lower alkyl.

"Alkenyl" refers to hydrocarbon radicals of 2-20 carbon atoms having one or more double bonds. Alkenyl radicals may be straight, branched, or cyclic. Exemplary alkenyl radicals include 1-pentenyl, 3-hexenyl, 1,4-octadienyl, 3,5-diethylcyclohexenyl, and the like. "Lower alkenyl" refers to alkenyl radicals having 2-8 carbon atoms.

5       The term "alkynyl" refers to hydrocarbon radicals of 2-20 carbon atoms having one or more triple bonds. Alkynyl radicals may be straight, branched, or cyclic. Exemplary alkynyl radicals include 1-pentynyl, 3-hexynyl, octa-2-yn-6-enyl, 3,5-diethylcyclohexynyl, and the like. "Lower alkynyl" refers to alkynyl radicals having 2-8 carbon atoms.

10       The term "cycloalkyl" refers to alkyl radicals of 3-20 carbon atoms having at least one ring of carbon atoms. "Bicycloalkyl" refers to alkyl radicals of 7-20 carbon atoms having at least two fused rings of carbon atoms (in which one or more carbon atoms are members of both rings). "Tricycloalkyl" refers to alkyl radicals of 7-20 carbon atoms having at least three fused rings of carbon atoms (in which one or more carbon atoms of each ring are simultaneously members of another ring).

15       The term "haloalkyl" refers to an alkyl radical substituted with one or more halogen atoms. Exemplary haloalkyl radicals include trifluoromethyl, 2,2,2-trifluoroethyl, 3-chlorocyclohexyl, 2-bromo-3-chlorocyclohexyl, 2,3-dibromobutyl, and the like.

20       The term "haloalkenyl" refers to an alkenyl radical substituted with one or more halogen atoms. Exemplary haloalkenyl radicals include 3-chloroprop-2-enyl, 4,4-dichlorobut-2-enyl, 5-bromo-3-methylcyclohex-2-enyl, and the like.

      "Aryl" refers to aromatic hydrocarbons having up to 14 carbon atoms, preferably phenyl or naphthyl. "Aryl-lower alkyl" refers to radicals of the form Ar-R-, where Ar is aryl and R is lower alkyl. "Aryloxy" refers to radicals of the form Ar-O-, where Ar is aryl. "Aryloxy-lower alkyl" refers to radicals of the form ArO-R-, where Ar is aryl and R is lower alkyl.

      The term "acyl" refers to a radical of the formula RCO-, in which R is H, alkyl as defined above, phenyl, benzyl or naphthyl. Exemplary acyl groups include acetyl, propionyl, formyl, t-butoxycarbonyl, benzoyl, and the like. "Lower acyl" refers to radicals wherein R is lower alkyl.

30



The term "halo" refers to a halogen radical, such as F, Cl, Br, or I.

The term "treatment" as used herein refers to reducing or alleviating symptoms in a subject, preventing symptoms from worsening or progressing, inhibition or elimination of the causative agent, or prevention of the infection or disorder in a subject who is free  
5 therefrom. Thus, for example, treatment of non-insulin dependent diabetes melitis (NIDDM) in a patient may be reduction in the serum levels of glucose. Treatment of Alzheimer's disease may be halting or retarding the progression of the disease (e.g., as measured by a reduction in the rate of dementia).

The term "glycogen synthase kinase 3" or "GSK3" as used herein refers to a  
10 protein originally identified by its phosphorylation of glycogen synthase as described in Woodgett *et al*, Trends Biochem Sci (1991) 16:177-81.

The term "biological condition mediated by GSK3 activity" as used herein refers to any biological or medical condition or disorder in which effective GSK3 activity is identified, whether at normal or abnormal levels. The condition or disorder may be  
15 caused by the GSK3 activity or may simply be characterized by GSK3 activity. That the condition is mediated by GSK3 activity means that some aspect of the condition can be traced to the GSK3 activity. It is expected that by the method of the invention, inhibiting the GSK3 activity will then prevent, ameliorate or treat the condition so characterized.


The term "CREB peptide" as used herein refers to a sequence within the CREB  
20 DNA-binding protein as described in Wang *et al*, Anal. Biochem (1994) 220:397-402.

#### General Methods and Detailed Description


The present invention provides for the inhibition of GSK3 activity, which includes, for example, inhibition of its kinase activity. By inhibiting GSK3 kinase  
25 activity, other activities downstream of GSK3 kinase activity are inhibited. For example, inhibition of the GSK3 kinase activity can result in the activation of glycogen synthase, because normally GSK3 acts constitutively in cells to inactivate glycogen synthase by direct phosphorylation. When GSK3 kinase activity is inhibited, glycogen synthase may activate leading to a cascade of events. GSK3 is also known to act as a kinase in a  
30 variety of other contexts, including but not limited to, for example, phosphorylation of c-jun,  $\beta$ -catenin, and tau protein. It is understood that inhibition of GSK3 kinase activity

can lead to a variety of effects in a variety of biological contexts. The invention is not limited, however, by any theories of mechanism of how the invention works.

Compounds of the invention may be prepared following standard techniques. See for example, T.C. Norman et al., *J. Am. Chem. Soc.* (1996) 118:7430-31, describing the synthesis of olomoucine derivatives. Briefly, compounds may be prepared from 2-amino-6-chloropurine, available, for example, from Aldrich Chemical Co. (St. Louis, MO).



2-amino-6-chloropurine



Olomoucine

Substitutions at R<sub>4</sub> (the N<sup>3</sup> position) may be introduced by reacting the starting material with a strong base (for example NaH) and an alkyl halide (for example, CH<sub>3</sub>I) in a solvent such as DMF. The C<sup>2</sup> amino group is alkylated by S<sub>N</sub>2 displacement with a protected 2-haloacetic ester, for example, *t*-butyl α-iodoacetate, using a strong base (e.g., NaH) in an aprotic solvent such as DMF. The protecting group (e.g., *t*-butyl) may be converted to the R<sub>2</sub> substitution, or may be removed to allow immobilization of the compound on a solid phase for further modification. For example, one may treat the ester with trifluoroacetic acid (TFA) and 1,4-dimethoxybenzene, followed by 1 eq PyBroP, 1 eq of *p*-nitrophenol, and 3 eq DIEA in CH<sub>2</sub>Cl<sub>2</sub>, followed by reaction with Rink resin, 0.06 M DIEA, and CH<sub>2</sub>Cl<sub>2</sub> to provide the purine derivative coupled to a solid support.

The R<sub>3</sub> substitution may be introduced directly by alkylation (as above) or acylation with a reactive acyl halide (e.g., propionyl chloride). R<sub>3</sub> groups bearing reactive moieties may require protection, for example a terminal OH may require protection with a *t*-butyl group. The C<sup>6</sup> position amino group and R<sub>1</sub> substitution may then be introduced by contacting the intermediate with a reagent of the formula R<sub>1</sub>-NH<sub>2</sub> (for example, 4-trifluoromethylbenzylamine) in DMF/DMSO. The resulting compound may then be cleaved from the resin, e.g., by treatment with CH<sub>2</sub>Cl<sub>2</sub>/TFA/Me<sub>2</sub>S at room

temperature. The resulting compound (with  $R_2 = NH_2$ ) may be modified to provide other  $R_2$  substitutions by standard techniques (esterification, etc.).

In presently preferred compounds of the invention,  $R_1$  is either a lipophilic alkyl (such as 3-methylbutyl, pentyl, hexyl, cyclohexyl, and the like, preferably 3-methylbutyl) or a substituted benzyl or pyridylmethyl radical, especially 4-fluorobenzyl, 3-pyridylmethyl, 4-pyridylmethyl, 4-trifluoromethylbenzyl, 4-methoxybenzyl, or 4-chlorobenzyl.  $R_2$  is preferably  $NH_2$ , and  $R_4$  is preferably lower alkyl, particularly methyl.  $R_3$  is preferably H or acyl, optionally substituted with  $NH_2$  or  $CH_3O$ , especially propionyl, 2-aminoacetyl, 2-methoxyacetyl, 3-methylbutyryl, 3-methoxypropionyl, butyryl, or 3-aminopropionyl.

Compounds of the invention are assayed for activity by standard techniques, preferably employing the GSK3 assay described in the examples below. The methods include methods to assay for GSK3 kinase activity in an *in vitro* or cell-based assay, a method to assay for inhibitors of binding to GSK3, and an *in vivo Drosophila* eye screening assay.

General aspects of the kinase activity assays are conducted as described in U.S. Patent No. 4,568,649; EP 154,734; and JP 84/52452, incorporated herein by reference, which describe kinase activity assays conducted for kinases other than GSK3. It is believed that GSK3 isoforms  $\alpha$  and  $\beta$  phosphorylate serine and threonine residues in the amino acid context serine-proline (SP) or threonine-proline (TP), as well as at the N-terminal serine in the motif SXXXXS, provided that the C-terminal serine in this sequence is prephosphorylated, as described in Wang *et al*, Anal Biochem (1994) 220:397-402 and Roach, J Biol Chem (1991) 266:14139-42.

Two of the methods for identifying specific inhibitors of GSK3 are an *in vitro* kinase assay and a cell-based kinase assay. Both kinase assays are performed similarly, with the distinction between them that the *in vitro* assay screens inhibitors that will act on the polypeptide GSK3, and the cell-based assay screens in addition for inhibitors that can act within the cell at any step in the process of expression of GSK3. Thus, the cell-based assay can screen for, for example, those inhibitors that act during transcription of GSK3 or that can act during intracellular post-transcriptional events in the process of making mature GSK3.

For the *in vitro* form of the assay, recombinant GSK3 is combined with the other components of the assay including a peptide substrate, and a compound of the invention. The assay published in Wang *et al* is a GSK3 assay makes use of a substrate peptide whose sequence is based on that of the GSK3 phosphorylation site in the CREB DNA-binding protein. In the published assay, the C-terminal serine in the SXXXXS motif is prephosphorylated by casein kinase II. However, a modified peptide of motif SXXXXS having an N-terminal anchor ligand can be synthesized with the C-terminal serine prephosphorylated (Chiron Mimotopes, Clayton, Australia). The substrate is then able to accomplish both binding to a substrate anchor at the N-terminal anchor ligand and to eliminate the need to phosphorylate the C-terminal serine as a separate step. The anchor ligand is a molecule or mechanism for keeping the substrate peptide present during a wash. For example, where the substrate anchor is biotin, especially in the case where the substrate is bound at the N-terminus to biotin, the anchor can be a molecule that binds biotin, for example, streptavidin.

To conduct the assay using microwells, scintillant may be present by coating the wells with a phosphorescent material, or by adding it later in a wash step. The scintillant can be purchased from Packard, Meriden, CT. Wells coated with scintillant are then coated with streptavidin. Where the scintillant is added later in a wash step, the streptavidin can be present on agarose beads. In any event, the streptavidin in the wells binds the biotin that contacts it. Where the substrate anchor is biotin, the radiolabel on the phosphorylated substrate that has been conjugated to the biotin will cause the phosphorescent material to phosphoresce.

Where the streptavidin is attached to phosphorescent agarose beads, binding a biotin-conjugated radiolabeled peptide substrate will cause the beads to phosphoresce and will be an indication of the inhibitory activity of the candidate inhibitor. In both the case of the wells lined with the phosphorescent material, and the agarose beads, a reduction in phosphorescence as compared to a control amount of phosphorescence measured under non-inhibitory conditions, indicates the presence of a functional inhibitor of GSK3 activity. If the peptide has been phosphorylated by GSK3 with  $^{32}\text{P}$ -labeled or  $^{33}\text{P}$ -labeled phosphate, radioactive decay will cause the phosphorescent material present in a microwell or mixed in agarose beads that are present in the reaction mixture to emit

light and the measure of the amount of light emitted will be a measure of the activity of GSK3 in the assay. Low activity of GSK3 observed in the presence of a candidate inhibitor, as compared to the activity of GSK3 in the absence of the inhibitor, may indicate that the inhibitor is functional and can inhibit GSK3 kinase activity. In any case,  
5 an equal amount of streptavidin should be loaded into each well or should be affixed to the agarose beads, and an equal amount of the beads added to each assay.

The cell-based assay includes in addition, a cell that can express GSK3, such as for example a cell transformed with the gene encoding GSK3, including regulatory control sequences for the expression of the gene. For conducting the cell-based assay,  
10 the cell capable of expressing GSK3 is incubated in the presence of a compound of the invention, the cell is lysed and the GSK3 is immunoprecipitated or otherwise purified, and the purified GSK3 is placed in contact with a peptide substrate, and radiolabeled phosphate-ATP. The amount of phosphorylation of the substrate is an indication of the degree of inhibition accomplished by the compound of the invention. During the cell-  
15 based assay, inhibition of GSK3 activity may occur either by inhibiting the expression of GSK3 or by inhibition of GSK3's protein kinase activity, both of which will be indicated by phosphorylation (or lack thereof) of the substrate peptide in the cell-based assay. However, one can determine which aspect is inhibited by assaying inhibition of GSK3 *in vitro* as described above.

20 An alternative assay that can be used to screen *in vivo* for inhibitors of GSK3 kinase activity is a *Drosophila* eye screen for inhibitors. The fly eye screen detects inhibitory activity by expressing GSK3 in *Drosophila* under the control of an eye-specific promoter. The eye specific promoter can be any promoter specific to expression of proteins in eye tissue, including but not limited to, for example, GMR as described in  
25 Hay *et al*, Development (1994) 120:2121-29, and the sevenless promoter, as described in Bowtell *et al*, Genes and Development (1988) 2:620-34. The screening assay for inhibitors of GSK3 activity is then conducted by feeding the flies food containing a compound of the invention. If the inhibitor is functional, the eye morphology reverts from mutant to wildtype. The expression of GSK3 under the control of the eye specific  
30 promoter leads to developmental defects which result in obvious aberrations in the external morphology of the external eye tissue. The mutant morphology that results in

these transgenic flies is called "roughening". These defects may depend on GSK3 activity, as indicated by a control experiment using developing flies expressing a GSK3 mutant that contains a mutated kinase domain. The fly eye cells transformed with a catalytically inactive GSK3 mutant are incapable of eliciting the rough eye morphological effects of the catalytically active counterpart.

*Drosophila* embryos are transformed by the method of Karess and Rubin, Cell (1984) 38:135-46 with a polynucleotide construct comprising a GSK3 coding sequence under the regulatory control of a GMR promoter. The flies are allowed to develop normally and are selected by eye morphology for successful transformants. Successful transformants have an aberrant morphology characterized by rough eye cell morphology that is detectable under a dissecting microscope. The transgenic flies are then fed food spiked with an appropriate dose of a compound of the invention. The amount of the inhibitor will depend on the deduced possible potency of the molecule as an inhibitor. The flies are fed a compound of the invention throughout third instar larval development, during which time they are observed for reversions of their eye morphology to wildtype or normal. Positives are identified. This method may also be applied as a primary screen to identify additional compounds of the invention that have positive activity. Variations to the protocol include injecting a compound of the invention into the third instar larvae of the transformants which are then observed for a reversion of the rough eye morphology to normal.

The compounds of the invention may be administered by a variety of methods, such as intravenously, orally, intramuscularly, intraperitoneally, bronchially, intranasally, and so forth. The preferred route of administration will depend upon the nature of the compound and the condition to be treated. Compounds may be administered orally if well absorbed and not substantially degraded upon ingestion (compounds of the invention are generally resistant to proteases). The compounds may be administered as pharmaceutical compositions in combination with a pharmaceutically acceptable excipient. Such compositions may be aqueous solutions, emulsions, creams, ointments, suspensions, gels, liposomal suspensions, and the like. Thus, suitable excipients include water, saline, Ringer's solution, dextrose solution, and solutions of ethanol, glucose, sucrose, dextran, mannose, mannitol, sorbitol, polyethylene glycol (PEG), phosphate,

acetate, gelatin, collagen, Carbopol®, vegetable oils, and the like. One may additionally include suitable preservatives, stabilizers, antioxidants, antimicrobials, and buffering agents, for example, BHA, BHT, citric acid, ascorbic acid, tetracycline, and the like. Cream or ointment bases useful in formulation include lanolin, Silvadene® (Marion),  
5 Aquaphor® (Duke Laboratories), and the like. Other topical formulations include aerosols, bandages, sustained-release patches, and the like. Alternatively, one may incorporate or encapsulate the compound in a suitable polymer matrix or membrane, thus providing a sustained-release delivery device suitable for implantation near the site to be treated locally. Other devices include indwelling catheters and devices such as the  
10 Alzet® minipump. Further, one may provide the compound in solid form, especially as a lyophilized powder. Lyophilized formulations typically contain stabilizing and bulking agents, for example human serum albumin, sucrose, mannitol, and the like. A thorough discussion of pharmaceutically acceptable excipients is available in Remington's Pharmaceutical Sciences (Mack Pub. Co.).

## 15 Examples

The examples presented below are provided as a further guide to the practitioner of ordinary skill in the art, and are not to be construed as limiting the invention in any way.

### Example 1


#### 20 (Preparation of Compounds)

Compounds of the invention were prepared following the method disclosed in T.C. Norman *et al.*, J. Am. Chem. Soc. (1996) 118:7430-31.

(A) 2-Amino-6-chloropurine was treated with NaH (1.1 eq) and CH<sub>3</sub>I (1 eq) in DMF. The product was treated with trifluoroacetic anhydride (3 eq) in CH<sub>2</sub>Cl<sub>2</sub>, then  
25 alkylated with *t*-butyl  $\alpha$ -iodoacetate (2 eq) and NaH (1.1 eq) in DMF. The reaction was quenched with K<sub>2</sub>CO<sub>3</sub> in MeOH. The product was then treated with trifluoroacetic acid (TFA) and 1,4-dimethoxybenzene, followed by PyBroP (1 eq), *p*-nitrophenol (1 eq), and DIEA (3 eq) in CH<sub>2</sub>Cl<sub>2</sub>, and coupled to Rink-derivatized polyethylene crowns

(Chiron Mimotopes, Clayton, Australia), 0.06 M DIEA, and  $\text{CH}_2\text{Cl}_2$  to provide the purine derivative coupled to a solid support ( $\text{R}_4$  = methyl).

The intermediate was acylated with 2-methoxyacetyl chloride (0.2 M) in the presence of 4-methyl-2,6-di-*t*-butylpyridine (0.25 M) in  $\text{CH}_2\text{Cl}_2$  at 37°C for 12 hours ( $\text{R}_2$  =  $\text{CH}_3\text{OCH}_2\text{CO}$ ). The resulting intermediate was reacted with 4-trifluoromethylbenzyl-  
5 amine (0.25 M) in DMF/DMSO (1:1 by volume) at 4°C for 16 h, followed by cleavage from the support by treatment with  $\text{CH}_2\text{Cl}_2$ /TFA/ $\text{Me}_2\text{S}$  at room temperature for 2 hours, to provide CHIR 21208:





(B) Proceeding as in part (A) above, the following compounds were made:

Compound ID	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>
21172	F <sub>3</sub> C- $\phi$ -CH <sub>2</sub> - (*)	NH <sub>2</sub>	H	CH <sub>3</sub>
21232	F <sub>3</sub> C- $\phi$ -CH <sub>2</sub> -	NH <sub>2</sub>	NH <sub>2</sub> CH <sub>2</sub> CO-	CH <sub>3</sub>
21220	F <sub>3</sub> C- $\phi$ -CH <sub>2</sub> -	NH <sub>2</sub>	CH <sub>3</sub> CH <sub>2</sub> CO-	CH <sub>3</sub>
20957	2-pyridylmethyl	NH <sub>2</sub>	H	CH <sub>3</sub>
20981	2-pyridylmethyl	NH <sub>2</sub>	(CH <sub>3</sub> ) <sub>2</sub> CHCH <sub>2</sub> CO	CH <sub>3</sub>
21005	2-pyridylmethyl	NH <sub>2</sub>	CH <sub>3</sub> CH <sub>2</sub> CO-	CH <sub>3</sub>
21132	(CH <sub>3</sub> ) <sub>2</sub> CHCH <sub>2</sub> CH <sub>2</sub>	NH <sub>2</sub>	CH <sub>3</sub> OCH <sub>2</sub> CO	CH <sub>3</sub>
21131	4-F- $\phi$ -CH <sub>2</sub> -	NH <sub>2</sub>	CH <sub>3</sub> OCH <sub>2</sub> CO	CH <sub>3</sub>
21196	F <sub>3</sub> C- $\phi$ -CH <sub>2</sub> -	NH <sub>2</sub>	(CH <sub>3</sub> ) <sub>2</sub> CHCH <sub>2</sub> CO	CH <sub>3</sub>
21095	4-F- $\phi$ -CH <sub>2</sub> -	NH <sub>2</sub>	H	CH <sub>3</sub>
21100	4-CH <sub>3</sub> O- $\phi$ -CH <sub>2</sub>	NH <sub>2</sub>	H	CH <sub>3</sub>
20951	cyclohexyl	NH <sub>2</sub>	H	CH <sub>3</sub>
20956	4-pyridylmethyl	NH <sub>2</sub>	H	CH <sub>3</sub>
- 21004	4-pyridylmethyl	NH <sub>2</sub>	CH <sub>3</sub> (CH <sub>2</sub> ) <sub>2</sub> CO	CH <sub>3</sub>
21075	4-Cl- $\phi$ -CH <sub>2</sub>	NH <sub>2</sub>	CH <sub>3</sub> (CH <sub>2</sub> ) <sub>2</sub> CO	CH <sub>3</sub>
21156	(CH <sub>3</sub> ) <sub>2</sub> CH(CH <sub>2</sub> ) <sub>2</sub>	NH <sub>2</sub>	NH <sub>2</sub> (CH <sub>2</sub> ) <sub>2</sub> CO	CH <sub>3</sub>

(\*) $\phi$  = phenyl

### Example 2

#### (Assay)

5 (A) A GSK3 $\beta$  gene was created in which a haemagglutinin (HA) epitope was fused to the N-terminal end of the GSK3 $\beta$  open reading frame in plasmid vector pCG, a pEVRF derivative, described in Giese *et al.* Genes & Development (1995) 9:995-1008, and in Matthias *et al.*, Nucleic Acids Res. (1989) 17:6418. pCG has a modified polylinker, and directs expression in mammalian cells from the human cytomegalovirus promoter/enhancer region. The resulting plasmid is pCG-HA-GSK3 $\beta$ . pCG-HA-GSK3 $\beta$  was transiently transfected into COS cells on 10 cm tissue culture plates using DEAE

Dextran, as described in Ausubel *et al* (1994) "Current Protocols In Molecular Biology", (Greene Publishing Associates and John Wiley & Sons, New York, NY).

The final density of cells was 70% confluent and these cells were lysed in 700  $\mu$ l Triton lysis buffer (20 mM TrisHCl, pH 7.9, 137 mM NaCl, 1.0% Triton® X-100, 10% glycerol, 1 mM NaVO<sub>3</sub>, 20 mM NaF, 30 mM pNpp, 15 mM PPI ). Anti-HA antibody (12CA5 monoclonal antibody purchased from Boehringer Mannheim, Indianapolis, IN) was added to 300  $\mu$ l of this lysate to a final concentration of 4  $\mu$ g/ml and incubated for 1h at 4°C. 100  $\mu$ l of a 50% slurry of protein A-Sepharose® beads were added for 2h at 4°C.

The beads were pelleted by centrifugation for 10 seconds in a microcentrifuge and washed with 0.5 M LiCl, 0.5% Triton® X-100, twice with phosphate buffered saline (PBS) and once with 10 mM TrisHCl, pH 7.5, 5 mM MgCl<sub>2</sub>, 1 mM DTT. All wash buffers contained 1 mM NaVO<sub>3</sub> and 25 mM  $\beta$ -glycerolphosphate. 33  $\mu$ l of the beads were analyzed by SDS-PAGE and western blotting with anti-HA antibody (12CA5) to quantitate the amount of HA-GSK3 $\beta$  present.

The remaining 17  $\mu$ l of beads was assayed according to the protocol of Wang *et al*, Anal Biochem (1994) 220:397-402. To each 17  $\mu$ l of pellet was added 3  $\mu$ l 10X GSK buffer (100 mM MgCl<sub>2</sub>, 20 mM DTT, 3M TrisHCl, pH 7.5), 0.7  $\mu$ l CREB peptide (either prephosphorylated or non-prephosphorylated, 5 mg/ml, Chiron Mimotopes Peptide Systems, San Diego, CA), 0.3  $\mu$ l 10 mM rATP, 1  $\mu$ l  $\gamma$ -<sup>32</sup>P-ATP (6000 Ci/mmol), 0.06  $\mu$ l 5 mg/ml of protein kinase inhibitor (a protein kinase-A inhibitor or PKI), and 25  $\mu$ l H<sub>2</sub>O. The reaction was allowed to proceed for 20 min at 22°C and then was stopped with 8  $\mu$ l 500 mM EDTA. 22  $\mu$ l of each reaction was spotted onto P81 phosphocellulose filter paper (purchased from Gibco-BRL Life Technologies, Gaithersburg, MD) washed 4 times for 5 minutes in 75 mM H<sub>3</sub>PO<sub>4</sub>. The filter papers were then assayed in a scintillation counter. Filter papers from experiments using the prephosphorylated CREB peptide substrate yielded counts of 85,000  $\pm$  5,000 cpm/min, whereas filter papers from experiments using the non-prephosphorylated CREB peptide substrate yielded counts of 5,000  $\pm$  1,000 cpm/min. The results indicated that the substrate was phosphorylated by GSK3 in the absence of an inhibitor, although the control substrate was not

phosphorylated. This experiment demonstrates the specificity of the peptide as a GSK3 substrate.

(B) The compounds prepared in Example 1 above were assayed for activity as follows:

5        A 96-well round bottom plate was blocked by incubation with 400  $\mu$ l/well 1% BSA/PBS for 60 min at room temperature. The blocking reagent was then aspirated. An enzyme/substrate buffer was prepared (1.225 ml 1M Tris-HCl, pH 7.5, 0.41 ml 1M  $MgCl_2$ , 41  $\mu$ l DTT, 250  $\mu$ l 500  $\mu$ g/ml GSK-3 $\beta$ , 9.5  $\mu$ l 5 mg/ml biotin-phosphopeptide, 33.1 ml 1% BSA/PBS), and 300  $\mu$ l enzyme/substrate/buffer was added to each well.

10        Varying concentrations of each compound were added to individual wells, or staurosporine in DMSO (final concentrations of staurosporine 100 nM or 20 nM). Next 50  $\mu$ l/well ATP mixture (3.85  $\mu$ l 10 mM cold ATP, 8  $\mu$ l hot ATP, 5.5 ml  $H_2O$ ) was added, and the reaction allowed to proceed for 180 min at room temperature.


15        Three streptavidin-coated Labsystems Combiplate 8 plates were blocked with 1% BSA/PBS, 300  $\mu$ l/well, for  $\geq 60$  min at room temperature, and the blocking reagent aspirated. Stopping reagent (50  $\mu$ M ATP, 20 mM EDTA) (100  $\mu$ l/well) was added to the streptavidin-coated plates, and 100  $\mu$ l of the enzyme reaction mixture transferred to the streptavidin-coated plates in triplicate. The plates were incubated at room temperature for 60 min, and washed 5X with PBS using a Corning plate washer. Finally, Microscint-  
20        20 scintillation fluid (200  $\mu$ l/well) was added to the plates, the plates sealed, and after incubating for 30 min, counted on a TopCount counter. The results were as follows:

Compound	%inhibition at 1 $\mu$ M
21208	63
21172	61
21232	58
21220	53
20957	50
20981	47
21005	45
21132	45
21131	43
21196	43
21095	41
21100	41
20951	40
20956	40
21004	40
21075	40
21156	40

The results demonstrated that the compounds of the invention were effective in inhibiting the kinase activity of GSK3.

What is claimed:

1. A compound of formula 1:



wherein

R<sub>1</sub> is alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl, substituted with 0-3 substituents selected from lower alkyl, halo, hydroxy, lower alkoxy, amino, lower alkyl-amino, and nitro;

R<sub>2</sub> is hydroxy, amino, or lower alkoxy;

R<sub>3</sub> is H, lower alkyl, lower acyl, lower alkoxy-acyl, or amino-acyl;

R<sub>4</sub> is H or lower alkyl;


and pharmaceutically acceptable salts and esters thereof.

2. The compound of claim 1, wherein R<sub>4</sub> is methyl.
3. The compound of claim 2, wherein R<sub>2</sub> is amino.
4. The compound of claim 3, wherein R<sub>1</sub> is pyridylmethyl.
5. The compound of claim 4, wherein R<sub>3</sub> is propanoyl.
6. The compound of claim 4, wherein R<sub>3</sub> is 3-methylbutanoyl.
7. The compound of claim 4, wherein R<sub>3</sub> is butanoyl.
8. The compound of claim 4, wherein R<sub>3</sub> is H.

9. The compound of claim 3, wherein  $R_1$  is 4-(trifluoromethyl)benzyl.
10. The compound of claim 9, wherein  $R_3$  is methoxyacetyl.
11. The compound of claim 9, wherein  $R_3$  is H.
12. The compound of claim 9, wherein  $R_3$  is aminoacetyl.
13. The compound of claim 9, wherein  $R_3$  is propanoyl.
14. The compound of claim 9, wherein  $R_3$  is 3-methylbutanoyl.
15. The compound of claim 3, wherein  $R_1$  is 4-fluorobenzyl.
16. The compound of claim 15, wherein  $R_3$  is methoxyacetyl.
17. The compound of claim 15, wherein  $R_3$  is H.
18. The compound of claim 3, wherein  $R_1$  is 4-methoxybenzyl and  $R_3$  is H.
19. The compound of claim 3, wherein  $R_1$  is cyclohexyl, and  $R_3$  is H.
20. The compound of claim 3, wherein  $R_1$  is 3-methylbutyl.
21. The compound of claim 20, wherein  $R_3$  is methoxyacetyl.
22. The compound of claim 20, wherein  $R_3$  is 3-aminopropanoyl.

23. The compound of claim 3, wherein  $R_1$  is 4-chlorobenzyl, and  $R_3$  is butanoyl.

24. A pharmaceutical composition, comprising:  
a compound of formula 1:



wherein

$R_1$  is alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl, substituted with 0-3 substituents selected from lower alkyl, halo, hydroxy, lower alkoxy, amino, lower alkyl-amino, and nitro;


$R_2$  is hydroxy, amino, or lower alkoxy;

$R_3$  is H, lower alkyl, lower acyl, lower alkoxy-acyl, or amino-acyl;

$R_4$  is H or lower alkyl;

or a pharmaceutically acceptable salts and esters thereof; and  
a pharmaceutically acceptable excipient.

25. A method of inhibiting GSK3, comprising:  
providing active GSK3; and  
contacting said GSK3 with a compound of formula 1:



wherein

R<sub>1</sub> is alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl,  
substituted with 0-3 substituents selected from lower alkyl, halo, hydroxy, lower  
alkoxy, amino, lower alkyl-amino, and nitro;

R<sub>2</sub> is hydroxy, amino, or lower alkoxy;


R<sub>3</sub> is H, lower alkyl, lower acyl, lower alkoxy-acyl, or amino-acyl;

R<sub>4</sub> is H or lower alkyl;

and pharmaceutically acceptable salts and esters thereof.



26. A method for treating a disorder mediated by GSK3, comprising:  
providing an effective amount of a compound of formula 1:



wherein

R<sub>1</sub> is alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl, substituted with 0-3 substituents selected from lower alkyl, halo, hydroxy, lower alkoxy, amino, lower alkyl-amino, and nitro;

R<sub>2</sub> is hydroxy, amino, or lower alkoxy;

R<sub>3</sub> is H, lower alkyl, lower acyl, lower alkoxy-acyl, or amino-acyl;

R<sub>4</sub> is H or lower alkyl;

or a pharmaceutically acceptable salt or ester thereof; and  
administering said composition to a subject having a disorder mediated by GSK3.

27. The method of claim 26, wherein said disorder is selected from the group consisting of diabetes and Alzheimer's disease.

# INTERNATIONAL SEARCH REPORT

Internat. Application No  
PCT/US 97/19472

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C07D473/16 A61K31/505

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 97 16452 A (CIBA GEIGY AG ;ZIMMERMANN JUERG (CH); CAPRARO HANS GEORG (CH); PET) 9 May 1997 see page 6 - page 7, line 1; claim 1; example 53	1
E	WO 97 41854 A (UNIV PENNSYLVANIA ;PRESIDENTS AND FELLOWS OF HARV (US)) 13 November 1997 see claim 1	1-27
P,A	WO 97 22360 A (MEDICAL RES COUNCIL ;UNIV DUNDEE (GB); COHEN PHILIP (GB); ALESSI D) 26 June 1997 see claims 1,31	1-27

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

29 January 1998

Date of mailing of the international search report

13. 02. 98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Gettins, M

# INTERNATIONAL SEARCH REPORT

Internat. Application No.  
PCT/US 97/19472

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>EP 0 616 032 A (MITSUBISHI CHEM IND) 21 September 1994 see claim 1</p> <p>-----</p>	1-27

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/ 19472

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 25-27  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 25-27 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat Application No

PCT/US 97/19472

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9716452 A	09-05-97	AU 7296896 A	22-05-97
WO 9741854 A	13-11-97	NONE	
WO 9722360 A	26-06-97	AU 1200497 A	14-07-97
EP 0616032 A	21-09-94	JP 6253835 A	13-09-94
		JP 6329551 A	29-11-94
		CA 2116460 A	03-09-94

**THIS PAGE BLANK (USPTO)**